Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Pharm Res. 2014 Feb 21;31(7):1855–1866. doi: 10.1007/s11095-013-1289-8

Fig. 2.

Fig. 2

Binding of ICAM-1-targeted nanocarriers to BBB cells. (A) Binding of FITC-labeled anti-ICAM NCs to control or TNFα-activated human brain astrocytes (ACs), endothelial cells (ECs), or pericytes (PCs) was quantified by fluorescence microscopy after 1 h incubation at 37°C. Scale bar = 10 μm. (B) Binding of anti-ICAM NCs to TNFα-activated cells was assessed over a period of 5 h. (A–B) Data are mean ± SEM. #Comparison to ECs within each condition; *comparison between TNFα and control for each cell type (p<0.05 by Student’s t-test).